Lentiviral vector transduced CD34+ cells
Phase 1Small molecule
Lentiviral vector transduced CD34+ cells is one of 15 small molecule programs targeting Severe Combined Immunodeficiency. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Severe Combined Immunodeficiency
#DrugCompanyPhaseTrials
1Rapamune
PPrism Pharmaceuticals
Approved
Retrovir
BBp Consulting, Inc
Approved
Atgam
NovartisPhase 2
Fludara
SanofiPhase 2
Tepadina
Alnylam PharmaceuticalsPhase 2
Kepivance
SSwedish Orphan Biovitrum
Phase 2
Campath
GGenzyme, a Sanofi Company
Phase 2
Neoral
NovartisPhase 1
Cellcept
RochePhase 1
Busulfex
Akero TherapeuticsPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Severe Combined Immunodeficiency1 trial
Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency
Recruiting·GGreat Ormond Street Hospital for Children NHS Foundation Trust·Phase 1·NCT03601286·5 enrolled
Gene Therapy1 trial
Lentiviral Gene Therapy for p47 AR-CGD
Recruiting·GGreat Ormond Street Hospital for Children NHS Foundation Trust·Phase 1/2·NCT05207657·5 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details